Levosimendan + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transient Ischemic Attack
Conditions
Transient Ischemic Attack, Stroke
Trial Timeline
Aug 1, 2008 → Sep 1, 2009
NCT ID
NCT00698763About Levosimendan + Placebo
Levosimendan + Placebo is a phase 2 stage product being developed by Orion Corporation for Transient Ischemic Attack. The current trial status is completed. This product is registered under clinical trial identifier NCT00698763. Target conditions include Transient Ischemic Attack, Stroke.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03576677 | Approved | UNKNOWN |
| NCT02261948 | Approved | Completed |
| NCT01721434 | Phase 2/3 | UNKNOWN |
| NCT01022983 | Approved | Withdrawn |
| NCT01065194 | Phase 3 | UNKNOWN |
| NCT00698763 | Phase 2 | Completed |
Competing Products
10 competing products in Transient Ischemic Attack
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets | Eli Lilly | Phase 1 | 33 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin | Pfizer | Phase 3 | 76 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Milvexian + Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Apixaban + Warfarin | Bristol Myers Squibb | Phase 3 | 76 |